Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors
- Study Title
- A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors
- Teva Identifier
- TV56278-ONC-10203
- ClinicalTrials.gov Identifier
- NCT06480552
- Study Status
- Recruiting
- Trial Condition(s)
- Advanced Solid Tumors
- Interventions
- Drug: TEV-56278
- Study Description
- Primary objectives: Characterize the safety and tolerability of TEV-56278 -Determine the Recommended Phase 2 Dose (RP2D). Evaluate antitumor activity of TEV-56278 -Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab. Determine a RP2D of TEV-56278 in combination with pembrolizumab
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 64 Years
- Trial Duration
- July 22, 2024 - February 25, 2031
- Phase
- Phase 1
